Papillomavirus Vaccines

Schiller, John T.

doi:10.1007/978-0-387-36523-7_14

Cited by 5 publications

(9 citation statements)

References 119 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…No correlation between antibody titres and administered antigen dose has been observed, indicating that the lowest dose of 50 mg/BPV1 VLP may suffice to achieve maximum immune responses. This agrees with the observation that PV VLPs are highly immunogenic even at small doses and without the use of adjuvant (Schiller 2007).…”

Section: Discussionsupporting

confidence: 92%

“…However, VLPs were not successful in inducing regression of pre‐existing tumours in cattle and human patients, thus lacking therapeutic efficacy (Schiller 2007). Chimeric BPV‐1 L1 VLPs expressing E7 oncoprotein (CVLP) were assessed as a possible therapeutic agent in sarcoid‐bearing horses (Mattil‐Fritz et al .…”

Section: Introductionmentioning

confidence: 99%

“…VLPs do not contain viral DNA and are, therefore, nonpathogenic. However, they resemble authentic virions in their ability to induce high titres of type-specific neutralising antibodies, the prerequisite for effective prophylactic vaccination (Zinkernagel 2003;Schiller 2007). VLP vaccination was successful in preventing infection with cottontail rabbit papillomavirus (CRPV) in domestic rabbits (Breitburd et al 1995), canine oral papillomavirus (COPV) in dogs (Suzich et al 1995) and BPV type 4 (BPV-4) in cattle .…”

Section: Introductionmentioning

confidence: 99%

“…Bivalent and tetravalent HPV VLP (HPV-6, -11, -16, -18) vaccines (Villa et al 2005) have been made commercially available worldwide. However, VLPs were not successful in inducing regression of pre-existing tumours in cattle and human patients, thus lacking therapeutic efficacy (Schiller 2007). Chimeric BPV-1 L1 VLPs expressing E7 oncoprotein (CVLP) were assessed as a possible therapeutic agent in sarcoid-bearing horses (Mattil-Fritz et al 2008) and donkeys (Ashrafi et al 2008), but immunisation did not lead to a significant reduction in the number of sarcoids.…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Safety and immunogenicity of BPV‐1 L1 virus‐like particles in a dose‐escalation vaccination trial in horses

Hainisch¹,

Brandt²,

Shafti-Keramat

et al. 2011

Equine Veterinary Journal

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 92%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Safety and immunogenicity of BPV‐1 L1 virus‐like particles in a dose‐escalation vaccination trial in horses

Hainisch¹,

Brandt²,

Shafti-Keramat

et al. 2011

Equine Veterinary Journal

View full text Add to dashboard Cite

show abstract

“…In humans and several animal species, immunization with VLPs of papillomaviruses has been shown to provide efficient protection from PV infection (Zinkernagel, ; Villa et al., ; Schiller, ). Recent studies conducted on horses demonstrated that BPV‐1 L1 protein VLPs constitute a safe and highly immunogenic vaccine candidate, and similar suggestions come from BPV‐4 L2 multimeric vaccines in bovines (Shafti‐Keramat et al., ; Jagu et al., ; Hainisch et al., ).…”

Section: Vaccinesmentioning

confidence: 99%

Bovine Papillomavirus: New Insights into an Old Disease

Bocaneti¹,

Altamura

Corteggio

et al. 2014

Transbound Emerg Dis

View full text Add to dashboard Cite

Bovine papillomaviruses (BPVs) are small DNA tumoral viruses able to induce benign cutaneous and/or mucosal epithelial lesions. Generally, the benign tumours affecting the skin or mucosa spontaneously regress, but under special circumstances, the defence system may be overwhelmed, thus leading to cancer, especially in the presence of immunosuppressant and mutagen agents from bracken fern. To date, thirteen different BPV genotypes have been associated with skin and mucosal tumours in cattle, and out of these, only four types (BPV-1, -2, -5 and -13) cross-infect other species. Recent investigations in vivo have revealed new insights into the epidemiology and pathogenesis of this viral infection. This review briefly discusses viral epidemiology, will give data on BPV genome structure and viral genes and will describe the cellular events and new aspects of both cutaneous and mucosal tumours in large ruminants. Finally, some aspects of active immunization will be described.

show abstract

Inoculation of young horses with bovine papillomavirus type 1 virions leads to early infection of PBMCs prior to pseudo-sarcoid formation

Hartl

Hainisch

Shafti-Keramat

et al. 2011

Journal of General Virology

View full text Add to dashboard Cite

Bovine papillomavirus types 1 and 2 (BPV-1 and BPV-2) are known to induce common equine skin tumours, termed sarcoids. Recently, it was demonstrated that vaccination with BPV-1 viruslike particles (VLPs) is safe and highly immunogenic in horses. To establish a BPV-1 challenge model for evaluation of the protective potential of BPV-1 VLPs, four foals were injected intradermally with infectious BPV-1 virions and with viral genome-based and control inocula, and monitored daily for tumour development. Blood was taken before inoculation and at weekly intervals. BPV-1-specific serum antibodies were detected by a pseudo-virion neutralization assay. Total nucleic acids extracted from tumours, intact skin and PBMCs were tested for the presence of BPV-1 DNA and mRNA using PCR and RT-PCR, respectively. Intralesional E5 oncoprotein expression was determined by immunofluorescence. Pseudo-sarcoids developed exclusively at sites inoculated with virions. Tumours became palpable 11-32 days after virion challenge, reached a size of ≤20 mm in diameter and then resolved in ≤6 months. No neutralizing anti-BPV-1 serum antibodies were detectable pre-or post-challenge. BPV-1 DNA was present in lesions but not in intact skin. In PBMCs, viral DNA was already detectable before lesions were first palpable, in concentrations correlating directly with tumour growth kinetics. PBMCs from two of two foals also harboured E5 mRNA. Immunofluorescence revealed the presence of the E5 protein in tumour Correspondence Sabine Brandt sabine.brandt@vetmeduni.ac.at.

show abstract

Papillomavirus Vaccines

Cited by 5 publications

References 119 publications

Safety and immunogenicity of BPV‐1 L1 virus‐like particles in a dose‐escalation vaccination trial in horses

Safety and immunogenicity of BPV‐1 L1 virus‐like particles in a dose‐escalation vaccination trial in horses

Bovine Papillomavirus: New Insights into an Old Disease

Inoculation of young horses with bovine papillomavirus type 1 virions leads to early infection of PBMCs prior to pseudo-sarcoid formation

Contact Info

Product

Resources

About